药理靶点与腹膜重塑
Pharmacologic targets and peritoneal membrane remodeling.
作者信息
Farhat Karima, Stavenuiter Andrea W D, Beelen Rob H J, Ter Wee Piet M
机构信息
Department of Nephrology,1 VU University Medical Center, and Department of Molecular Cell Biology and Immunology,2 VU University, Amsterdam, Netherlands.
出版信息
Perit Dial Int. 2014 Jan-Feb;34(1):114-23. doi: 10.3747/pdi.2011.00332.
Abstract
Peritoneal dialysis (PD) is associated with functional and structural changes of the peritoneal membrane, also known as peritoneal remodeling. The peritoneal membrane is affected by many endogenous and exogenous factors such as cytokines, PD fluids, and therapeutic interventions. Here, we present an overview of various studies that have investigated pharmacologic interventions aimed at regression of peritoneal damage and prolongation of PD treatment.
摘要
腹膜透析（PD）与腹膜的功能和结构变化相关，也称为腹膜重塑。腹膜受到许多内源性和外源性因素的影响，如细胞因子、腹膜透析液和治疗干预措施。在此，我们概述了各项研究，这些研究调查了旨在逆转腹膜损伤和延长腹膜透析治疗时间的药物干预措施。
相似文献
1
Pharmacologic targets and peritoneal membrane remodeling.药理靶点与腹膜重塑
Perit Dial Int. 2014 Jan-Feb;34(1):114-23. doi: 10.3747/pdi.2011.00332.
2
The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis.二肽丙氨酰谷氨酰胺可改善腹膜纤维化，并在腹膜透析过程中减弱白细胞介素-17依赖性途径。
Kidney Int. 2016 Mar;89(3):625-35. doi: 10.1016/j.kint.2015.12.005. Epub 2016 Jan 8.
3
Peritoneal Membrane Preservation.腹膜保护
Semin Nephrol. 2017 Jan;37(1):77-92. doi: 10.1016/j.semnephrol.2016.10.009.
4
Complement system activation and peritoneal membrane alterations: Culprit or innocent bystander?补体系统激活与腹膜结构改变：罪魁祸首还是无辜旁观者？
Perit Dial Int. 2020 Mar;40(2):115-123. doi: 10.1177/0896860819896242. Epub 2020 Jan 13.
5
Mechanisms and interventions in peritoneal fibrosis.腹膜纤维化的机制与干预措施。
Clin Exp Nephrol. 2012 Feb;16(1):109-14. doi: 10.1007/s10157-011-0533-y. Epub 2011 Sep 21.
6
Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis.预防腹膜透析患者腹膜纤维化的策略：基于腹膜炎症和血管生成的新见解。
Front Med. 2017 Sep;11(3):349-358. doi: 10.1007/s11684-017-0571-2. Epub 2017 Aug 8.
7
New developments in peritoneal fibroblast biology: implications for inflammation and fibrosis in peritoneal dialysis.腹膜成纤维细胞生物学的新进展：对腹膜透析中炎症和纤维化的影响
Biomed Res Int. 2015;2015:134708. doi: 10.1155/2015/134708. Epub 2015 Oct 1.
8
Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.口服补充舒洛地特可抑制腹膜灌注大鼠模型中的新生血管形成。
Nephrol Dial Transplant. 2012 Feb;27(2):548-56. doi: 10.1093/ndt/gfr370. Epub 2011 Jul 12.
9
Pathophysiological Mechanisms of Peritoneal Fibrosis and Peritoneal Membrane Dysfunction in Peritoneal Dialysis.腹膜透析中腹膜纤维化和腹膜功能障碍的病理生理机制。
Int J Mol Sci. 2024 Aug 7;25(16):8607. doi: 10.3390/ijms25168607.
10
TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.TGF-β1-VEGF-A 通路诱导接受腹膜透析患者的新生血管形成和腹膜纤维化。
Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F167-F180. doi: 10.1152/ajprenal.00052.2017. Epub 2017 Oct 4.
引用本文的文献
1
Deletion of p38 MAPK in macrophages ameliorates peritoneal fibrosis and inflammation in peritoneal dialysis.巨噬细胞中 p38MAPK 的缺失可改善腹膜透析中的腹膜纤维化和炎症。
Sci Rep. 2024 Sep 11;14(1):21220. doi: 10.1038/s41598-024-71859-5.
2
STAT3/HIF-1α signaling activation mediates peritoneal fibrosis induced by high glucose.STAT3/HIF-1α 信号通路激活介导高糖诱导的腹膜纤维化。
J Transl Med. 2021 Jun 30;19(1):283. doi: 10.1186/s12967-021-02946-8.
3
Is there such a thing as biocompatible peritoneal dialysis fluid?是否存在生物相容的腹膜透析液？
Pediatr Nephrol. 2017 Oct;32(10):1835-1843. doi: 10.1007/s00467-016-3461-y. Epub 2016 Oct 8.
4
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.表皮生长因子受体的抑制作用可阻断腹膜纤维化的发展与进程。
J Am Soc Nephrol. 2016 Sep;27(9):2631-44. doi: 10.1681/ASN.2015030299. Epub 2015 Dec 17.
本文引用的文献
1
Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol − a preliminary study.帕立骨化醇治疗后腹膜透析患者腹膜通透性和蛋白尿的变化——一项初步研究
Clin Nephrol. 2012 Aug;78(2):93-9. doi: 10.5414/CN107570.
2
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.生物相容性与标准液对腹膜透析结果的影响。
J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.
3
Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.吡格列酮治疗 12 周可显著改善持续性不卧床腹膜透析患者的代谢紊乱和减轻炎症——一项随机交叉试验。
Perit Dial Int. 2012 Sep-Oct;32(5):507-15. doi: 10.3747/pdi.2011.00116. Epub 2012 Mar 1.
4
The effect of vitamin D derivatives on vascular calcification associated with inflammation.维生素D衍生物对与炎症相关的血管钙化的影响。
Nephrol Dial Transplant. 2012 Jun;27(6):2206-12. doi: 10.1093/ndt/gfr555. Epub 2011 Oct 24.
5
Pharmacological modulation of peritoneal injury induced by dialysis fluids: is it an option?透析液诱导的腹膜损伤的药理学调节：这是一种选择吗？
Nephrol Dial Transplant. 2012 Feb;27(2):478-81. doi: 10.1093/ndt/gfr543. Epub 2011 Sep 29.
6
Angiogenesis in peritoneal dialysis.腹膜透析中的血管生成。
Kidney Blood Press Res. 2011;34(4):245-52. doi: 10.1159/000326953. Epub 2011 Jun 21.
7
L-carnitine is an osmotic agent suitable for peritoneal dialysis.左旋肉碱是一种适合腹膜透析的渗透剂。
Kidney Int. 2011 Sep;80(6):645-54. doi: 10.1038/ki.2011.117. Epub 2011 Apr 27.
8
Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.苯磷汀可预防腹膜透析中腹膜和肾脏损伤。
J Am Soc Nephrol. 2011 May;22(5):914-26. doi: 10.1681/ASN.2010070750. Epub 2011 Apr 21.
9
Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis.人类腹膜中激素受体和纤维生成标志物表达的差异——预防包裹性腹膜硬化症治疗靶点的启示。
Perit Dial Int. 2011 May-Jun;31(3):291-300. doi: 10.3747/pdi.2010.00118. Epub 2011 Mar 31.
10
The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both?中性 pH 值、低 GDP 腹膜透析液的生物相容性：是仅在实验室有益，还是在病床和实验室均有益？
Kidney Int. 2011 Apr;79(8):814-24. doi: 10.1038/ki.2010.515. Epub 2011 Jan 19.
Zotero 插件